Jazz Pharmaceuticals (JAZZ) Liabilities and Shareholders Equity (2010 - 2026)

Jazz Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $11.9 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 2.82% year-over-year to $11.9 billion; the trailing twelve-month figure through Mar 2026 stood at $45.8 billion (down 2.85% YoY), and the FY2025 full-year result was $11.7 billion, down 2.94% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $11.9 billion, up from $11.7 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $12.3 billion in Q3 2024, with the low at $10.4 billion in Q3 2022.
• Average Liabilities and Shareholders Equity over 5 years is $11.4 billion, with a median of $11.4 billion recorded in 2025.
• Peak annual rise in Liabilities and Shareholders Equity reached 74.19% in 2022, while the deepest fall reached 16.78% in 2022.
• Tracing JAZZ's Liabilities and Shareholders Equity over 5 years: stood at $10.8 billion in 2022, then rose by 5.15% to $11.4 billion in 2023, then climbed by 5.43% to $12.0 billion in 2024, then retreated by 2.94% to $11.7 billion in 2025, then increased by 1.72% to $11.9 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $11.9 billion (Q1 2026), $11.7 billion (Q4 2025), and $11.4 billion (Q3 2025), per Business Quant data.

Peer Comparison